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The emergence of antibiotic resistant bacteria and the failure of the existing antibacterial 
therapeutics call for development of novel treatment strategies. Furthermore, the formation of 
bacterial biofilms restricts the drugs penetration and efficiency, causing life-threatening 
infections. Bacterial attachment and biofilm formation are regulated by the cell-to-cell 
communication phenomenon called quorum sensing (QS). In this work, antimicrobial silver 
nanoparticles (AgNPs) are decorated in a Layer-by-Layer fashion with the oppositely charged 
aminocellulose (AM) and acylase to generate hybrid nanoentities with enhanced antibacterial 
and antibiofilm activities as well as reduced cytotoxicity. Acylase, a quorum quenching 
enzyme that degrades the QS signals in the extracellular environment of bacteria, disrupts the 




minimum inhibitory concertation of the AgNPs templates towards Gram-negative 
Pseudomonas aeruginosa (P. aeruginosa). The hybrid nanoparticles in 8-fold lower 
concentration than the AgNPs, inhibit 45 % of the QS-regulated virulence factors produced by 
the reporter C. violaceum bacterial strain and reduce by 100 % the P. aeruginosa biofilm 
formation. Moreover, the sequential deposition of antibacterial/antibiofilm active and 
biocompatible biopolymers onto the AgNPs allows the engineering of safe nanomaterials that 




Antimicrobial drug resistance has become a serious public health threat and one of the leading 
causes of death worldwide.
[1]
 The failure of the existing antibiotic therapies is the reason for 
the increased mortality and morbidity in hospitals, as well as the huge economic burden.
[2]
 
Besides the specific resistant mechanisms, such as i) modification of the drug target, ii) 
antibiotics degradation and iii) over-expression of efflux pumps for the exportation of 
antibiotics out of the cell, bacteria are able to express biofilm-specific phenotypes, which are 
extremely tolerant to the most of the currently available antimicrobials.
[3,4]
 Bacterial biofilms 
are surface attached community of cells encased in a self-produced polymeric matrix that 
suppress the host immune response and protect the pathogens from the antimicrobial agents. 
Biofilm formation begins with bacterial attachment to the host tissues or non-living medical 
surfaces, which is followed by the production of specific signaling molecules. These signals, 
specifically recognized by Gram-negative bacteria in the quorum sensing (QS) process, are 
acyl-homoserine lactones (AHL). QS governs the virulence factors production, biofilm 
formation and establishment of severe bacterial infections.
[5,6]
 The community-acquired 




treatments and therefore calls for the development of new antimicrobial alternatives with 
lower potential for resistance selection.
[7]
 
The introduction of new antibiotic analogues with similar to the original drug structural and 
functional characteristics is only a short-term antibacterial strategy, compared to the time and 
resources consuming development of the next generation antibiotics.
[2]
 In this respect, 
nanoparticles (NPs) have brought new perspectives for improving the antibacterial efficacy of 
antibiotics due to the high surface to volume ratio and their unique physical and chemical 
properties.
 
Nano-formulated antimicrobials have shown enhanced antibacterial activity 
compared to their bulk counterparts because of the improved interaction with bacterial 
membrane and easier access to the target site.
[8]
 Furthermore, the nano-form enhances the 
penetration of the active in the biofilm structure, which is crucial in determining the treatment 
efficacy of the antimicrobials.
[9]
 
Silver nanoparticles (AgNPs) are one of the most widely exploited nanobactericides in wound 
dressing materials, medical devices and textiles.
[10]
 Despite their strong antibacterial potential 
against susceptible and drug-resistant bacteria, the use of AgNPs in medical practice is limited 
because of their low stability, toxicity and the possibility to invoke resistance in bacteria.
[11,12]
  
To address these issues, green nanotechnology approach based on biocompatible compounds, 
instead of toxic chemicals, has been employed for the synthesis of stable AgNPs with reduced 
toxicity.
 
Our group has integrated cationic biopolymers, e.g. chitosan and aminocellulose 
(AM),
[13-15]
 and enzymes, e.g. amylase, with Ag
0
 into the same hybrid nanosystem to 
eliminate bacteria and their biofilms, without affecting human cells viability. Amino-bearing 
biopolymers are membrane-damaging bactericides with high efficiency towards both Gram-
positive and Gram-negative bacteria and reduced possibility for resistance development.
[16]
 
On the contrary, hydrolytic quorum quenching enzymes (QQE) such as acylase and lactonase 
that degrade the QS signals in the extracellular environment and disrupt the QS, without 
killing bacteria,
[17,18] 




virulent and more susceptible to lower antibiotic dosage.
[19-22]
 We have applied these QQEs 




In this work, the QQE acylase and amino-bearing biopolymer AM were used for the first time 
for layer-by-layer (LbL) coating of AgNPs templates in order to obtain hybrid 
enzyme/biopolymer/metal NPs with enhanced antibacterial and antibiofilm activities against 
the Gram-negative Pseudomonas aeruginosa. LbL is a simple and versatile self-assembling 
technology of oppositely charged molecules used for production of multifunctional 
nanocoatings
[25]
 on inert macro, micro and nano-sized templates
[26]
 under mild conditions, 
without the need for any chemical modification.
[27]
 Herein, the coating of antibacterial AgNPs 
with membrane disrupting biopolymer is expected to create high local positive charge density, 
which synergistically with the activity of the nano-sized template will improve the interaction 
of the novel hybrid NPs with bacterial membranes and potentiate the bactericidal activity of 
AgNPs at lower dosage. Furthermore, the inclusion of acylase in the nano-hybrids will inhibit 
the establishment of P. aeruginosa biofilm, making the pathogen susceptible to low and safe 
to human cells AgNPs concentrations. The functionality of the novel NPs will be evaluated in 
terms of QS inhibition potential, antibacterial activity and capacity to prevent and eradicate P. 
aerugnosa biofilms. Finally, the cytotoxicity of the NPs will be assessed in vitro towards 
human fibroblasts cells. 
 
2. Results and Discussions 
2.1. Nanoparticles Characterization  
AgNPs were produced and used as an active antibacterial NP-template for LbL self-
assembling with amino-bearing AM and anti-QS acylase. The synthesis of AgNPs was carried 
out in an aqueous solution as previously described.
[28]
 The change from transparent to green-




AgNPs formation (Figure S1, Supporting Information). The resulting NPs, with -56,15 mV 
zeta-potential and 20-25 nm size (Table S1, Supporting Information), were then 
sequentially coated with oppositely charged AM and acylase in an LbL fashion. The 
positively charged AM was applied as a first layer, changing the AgNPs zeta potential to + 
30.8 mV. Subsequently, the deposition of negatively charged QQE acylase switched the NPs 
surface charge to – 29.97 mV forming stable LbL Ag@AM_AC NPs (Figure 1B).  
The morphology of the LbL Ag@AM_AC NPs was further assessed using transmission 
electron microscopy (TEM). TEM images (Figure 1C, D) revealed the generation of quasi-
spherical in shape NPs with an average size of 30-35 nm, which are embedded in a hybrid 
macromolecular shell of AM and AC. The data revealed a small size of the NPs (Figure 1E). 
The STEM mapping and energy dispersive x-ray (EDX) spectroscopy of an individual LbL 
Ag@AM_AC NP further confirmed the presence of elemental silver in the metal NP core 
(bright central region), as well as carbon and oxygen in the AM and AC shell (Figure 1F). 
The copper ions detected by the EDX (Figure 1G) are from the grid used for the analysis. 
The activity of acylase in the LbL Ag@AM_AC NPs was further assessed following a 
colorimetric method and an in vitro bioassay with a reporter bacterial strain. In the 
colorimetric assay, the enzymatic activity of acylase was confirmed via the degradation of N-
acetyl-L-methionine substrate to L-methionine and the subsequent development of purple 
color upon interaction with ninhydrin (Figure S2, Supporting Information).
[23]
  
The QQ activity of the enzyme after its deposition onto the AgNPs templates was 
demonstrated through the degradation of the QS signals in Chromobacterium violaceum (C. 
violaceum) CV026. C. violaceum CV026 is mini-Tn5 mutant that produces a purple pigment 
(violacein) upon the addition of AHL signaling molecules.
[29]
 The QQE degrades the AHL 
signals, consequently inhibiting the violacein production.
[30]
 This Gram-negative bacterium 
has been used in our group to demonstrate the anti-QS potential of acylase from Aspergillus 
melleus.
[23,24]








degraded the AHLs and disrupted the QS process, reducing the violacein production by 45 % 
(Figure 2), without affecting C. violaceum growth (Figure S3, Supporting Information). 
The same amount of pristine AgNPs, however, did not influence the production of this 
pigment, confirming the presence of active enzyme on the nano-template, which is able to 
quench the signals and inhibit the QS-regulated behavior in the Gram-negative pathogen P. 
aeruginosa. Interruption of QS in the extracellular environment is a new approach for 
attenuation of bacterial virulence and boosting the bactericidal activity of existing 
antimicrobials at lower dosage.
[31]
 Moreover, the anti-QS based strategy reduces the risk of 
drug resistance development. 
 
2.2. Antibacterial efficiency of AgNPs and LbL Ag@AM_AC NPs 
The minimal inhibitory concertation (MIC) of the AgNPs template and the developed LbL 
Ag@AM_AC NPs was determined against P. aeruginosa by a standard broth dilution 
method.
[9]
 The lowest concentrations, where visible bacterial growth (OD=0) was not 
observed, were considered as MIC. The stand-alone AgNPs demonstrated antibacterial 




 (Figure 3). However, the 
functionalization of AgNPs with AM enhanced their bactericidal activity by 2-fold, as 
anticipated on the basis of our previous findings.
[27]
 The nanoscale transformation of amino-
bearing polymers enhanced the availability of the positively charged amino groups, resulting 




Furthermore, the inclusion of QQ acylase improved 4-fold the NPs inhibitory efficacy against 
P. aeruginosa (Figure 3). The ability of acylase to interfere with QS in P. aeruginosa and 
attenuate its virulence is thought to potentiate the bactericidal capacity of the actives, 
lowering their antibacterial effective concentrations. In order to outline the role of the enzyme, 




BSA, instead of AC (Figure S4, Supporting Information). The obtained control NPs 
possess similar physicochemical properties (i.e. size, zeta-potential and concentration) as the 
LbL Ag@AM_AC NPs, but were less active towards P. aeruginosa, confirming the 
synergistic role of acylase and AM in enhancing the antibacterial properties of the AgNPs 
template. The bactericidal activity of LbL Ag@AM_AC was further confirmed after plating 
onto selective Cetrimide agar. The LbL Ag@AM_AC NPs completely eliminated the P. 
aeruginosa cells at lower concentrations when compared to the same amount of AgNPs due to 
the complementary action of the bactericidal nano-sized core and the anti-QS acylase (Figure 
S4B, Supporting Information). Although, our pervious findings have shown that higher 
number of layers is needed to introduce desired antibacterial functionality on inert NP 
template, herein the deposition of more AM/acylase layers did not result in enhanced 
bactericidal activity.
[27]
 In contrary, more layers diminished the effect of the active AgNPs 
template and no synergy between the nanoform and polymeric AM/acylase was observed 
(data not shown). 
In order to study the physical changes of bacteria upon exposure to LbL Ag@AM_AC NPs, 
ultrastructural analysis using TEM was performed. A clear difference in the morphology 
between the treated (Figure 3B) and non-treated (Figure 3C) P. aeruginosa cells was 
observed. The LbL Ag@AM_AC NPs adsorbed onto the bacterium surface, leading to outer 
membrane disintegration and cytoplasmic leakage. Moreover, some of the LbL NPs were 
observed in the cytoplasmic space, indicating their ability to penetrate the membrane and 
affect essential for bacterial cells life-supporting metabolic processes as cells respiration 
(Figure 3C). It could be anticipated that the novel hybrid NPs kill bacteria via a combination 
of mechanisms including interaction with bacterial cell wall, reactive oxygen species (ROS) 
production
33
 and modulation of microbial signal transduction pathways.
34
 The potential of 
AgNPs template and LbL Ag@AM_AC NPs to generate ROS and kill P. aeruginosa was 




2, 2-azobis (2-amidinopropane) dihydrochloride (AAPH), the AgNPs and LbL Ag@AM_AC 
NPs did not generate ROS similar to the negative control containing only bacteria (Figure S5, 
Supporting Information). Thus, the bactericidal AgNPs and LbL Ag@AM_AC NPs cause 
cellular death without ROS-related oxidative damage.  
2.3. Antibiofilm activity  
P. aeruginosa is an opportunistic Gram-negative pathogen, responsible for variety of difficult 
to treat infections
[35]
 due to its ability to attach and form robust biofilm structures on medical 
devices and living tissues, that aggravate the host immune response and resist the antibiotic 
therapies. P. aeruginosa biofilm formation is a complex bacterial mode of growth, which is 
under the control of QS. 
[35]
 In this work, we aimed to develop hybrid NPs that interrupt the 
QS process via degradation of the AHL signaling molecules and thus effectively inhibit and 
eliminate the biofilm growing P. aeruginosa cells at lower concentrations than the stand alone 
AgNPs. The antibiofilm activity (biofilm growth inhibition and elimination) of the NPs was 
studied by crystal violet and Live/dead™ BacLight™ assays to quantify the total biofilm 
mass and visualise the live and dead cells on a model polystyrene surface.  
2.3.1. Inhibition of P. aeruginosa biofilm formation by LbL Ag@AM_AC NPs 
P. aeruginosa was cultured in the presence of different concentrations of LbL Ag@AM_AC 
NPs and AgNPs for 24 h to determine the minimum biofilm inhibitory concentration (MBIC). 
The MBIC is defined as the concentration at which the total biofilm mass was inhibited by > 
90 %, when compared to the control with only bacteria corresponding to 100 % biofilm 









) (Figure 4A).  
The obtained microscopic images of P. aeruginosa biofilms after 24 h incubation with LbL 
Ag@AM_AC NPs at the determined MBIC further confirmed their enhanced antibiofilm 
activity (Figure 4B). The LbL Ag@AM_AC NPs at their MBIC completely inhibited the 




contrast, the AgNPs at the same concentration, showed negligible antibiofilm activity and 
formed typical for the mature biofilm bacterial clusters, similar to the control (only P. 
aeruginosa) (Figure 4B). All these results indicated the synergy between the bactericidal 
nano-sized template and the antibiofilm acylase enzyme. Interrupting the QS process through 
acylase-catalysed degradation of bacterial signals in the extracellular bacterial space have 
been shown very effective for inhibiting P. aeruginosa virulence and establishment of drug 
resistant biofilms, without bacteria killing.
[36]
 Herein, the deposition of acylase on the 
bactericidal AgNPs yielded multifunctional nanoentities able to inhibit the QS-regulated 
pathological processes and at the same time completely eliminate the biofilm forming bacteria 
at lower dosage of the bactericidal agent, thus exerting less evolutionary pressure on bacteria 
for resistance development. The engineered LbL NPs demonstrated high potential for 
eradicating P. aeruginosa and therefore could be exploited in the development of coatings on 
medically relevant surfaces for preventing biofilm associated infections.  
 
2.3.2. Elimination of P. aeruginosa biofilms with LbL Ag@AM_AC NPs 
P. aeruginosa cells in already established biofilms are enclosed in an extracellular polymeric 
matrix (EPM), which is the bacterium protective barrier against the action of the immune 
system and the effective penetration of the conventional drugs.
[35]
 Therefore, the potential of 
the LbL Ag@AM_AC NPs to overcome the inherent biofilm resistance and penetrate through 
the P. aeruginosa biofilm was further assessed. The minimum biofilm eradication 
concentration (MBEC) of the LbL Ag@AM_AC NPs, i.e. the lowest NPs concentration at 
which bacteria fail to re-grow, was determined using crystal violet. The MBEC of the novel 









) (Figure 5A). 
Although the anti-QS approaches are considered more relevant in inhibiting the early stage of 




communities, several studies have demonstrated the ability of acylase to reduce bacterial 
biofilms. These findings are in line with the assumption that the QS signaling has an 
important role for maintaining the integrity of already formed P. aeruginosa biofilm.
[37-39]
 In 
particular, the process is part of the extracellular DNA release and the structural stability of 
the biofilm.
[35]
 We believe that the nano-formulated acylase weakens and destabilises the 
protective EPM barrier, enhancing the access of therapeutic NPs to the bacterial cells in the 
mature biofilm. Moreover, decorating the AgNPs with a cationic polymer adds an additional 
mechanism for bacteria killing, through membrane disruption, potentiating the antibacterial 
and antibiofilm activities of AgNPs at lower concentrations.
[40,41]
 Previous results of our 
group, have demonstrated enhanced antibacterial and biofilm activities of nano-formulated 
antimicrobials (such as AM, penicillin and vancomycin) in comparison to their bulk 









) on established biofilms was assessed with fluorescence microscopy after Live/Dead 
staining. A significant decrease in the cell viability and biofilm density (most of the cells were 
stained in red) was observed, when the 24 h old biofilm was treated with LbL Ag@AM_AC 
NPs (Figure 5B). In contrast, the application of unmodified AgNPs resulted in reduced cells 
viability, however, without any significant decrease/elimination of the total biofilm mass 
(Figure 5B). Therefore, the novel LbL Ag@AM_AC NPs possess great therapeutic potential 
and could be employed in the design of topical formulations for treatment of severe skin 
infections or for coating of medical devices and surfaces in contact with humans.  
 
2.4. Biocompatibility assessment 
AgNPs are known antibacterial agent widely used as disinfectant or coating of medically 
relevant surfaces,
[43]




biomedical application. Therefore, the viability of human cells upon exposure to AgNPs 
template and LbL-decorated NPs at their bactericidal concentrations was assessed after 24 h 
of incubation. AgNPs demonstrated high toxicity and reduced by 20 % the viability of human 
cell (Figure 6A), while nearly 100 % of the skin cell fibroblasts were viable in the presence 
of functionalised with AM and acylase AgNPs (Figure 6A).  Unlike the AgNPs, the LbL 
Ag@AM_AC NPs did not cause cell morphology changes compared to the negative control 
(Figure 6B). The toxicity of AgNPs greatly depends on their concentration, size, shape, 
surface chemistry/coating and dissolved silver ions from the NPs.
[44]
 Here, to benefit from the 
outstanding performance of AgNPs in terms of microbial elimination and at the same time 
minimise their toxicity, we engineered in a “safe by design” approach novel biomaterial-
coated AgNPs.  Functionalisation of the AgNPs with biocompatible and antibacterial 
polymers and enzymes is a promising strategy to change the AgNPs toxicity profile and boost 
their bactericidal properties.
44
    
 
3. Conclusion 
In this work, AgNPs were LbL coated with antimicrobial AM and QQ acylase in order to 
generate safe and highly efficient antibacterial and antibiofilm hybrid nano-entities. The 
bilayered decoration of AgNPs template resulted in 4-fold enhanced bactericidal activity 
towards the Gram-negative P. aeruginosa due to the synergy between the metal core and the 
nanoformulated antibacterial AM and antibiofilm acylase. Moreover, these hybrid NPs were 
able to degrade the AHL signaling molecules of Gram-negative bacteria, inhibiting the QS 
regulated biofilm formation by P. aeruginosa at lower concentrations than the pristine AgNPs. 
The anti-QS acylase has also affected the pathogenicity and the integrity of already 
established P. aeruginosa biofilm, increasing the bacterium susceptibility to antibacterial 




safe-by-design approach for development of metal-based nanoantimicrobials with decreased 
toxicity to mammalian cells and improved efficacy. The combination of membrane-disrupting 
AM and QQ acylase on the AgNPs surface provides an innovative tool for treatment of 
bacterial infections, at minor risk for resistance development.  
 
4. Experimental Section  
Materials: Microcrystalline cellulose (Avicel PH-101 from Fluka) was used for the 
preparation of the 6-deoxy-6-(ω-aminoethyl) aminocellulose (AM) derivative as previously 
described.
[27]
 Acylase from Aspergillus melleus (E.C 3.5.1.14; 4.5 % (w/w) protein content 
and 2.49 U mg
-1





) and the human foreskin fibroblast cells (ATCC
®
 
CRL-4001™, BJ-5ta) were obtained from American Type Culture Collection (ATCC LGC 
Standards, Spain). AlamarBlue
®
 cell viability reagent was purchased from Invitrogen, Life 
Technologies Corporation (Spain). Ultrapure water (MilliQ
®
 plus system, Millipore) with 
18.2 MΩ.cm resistivity was used in all experiments. All other chemical and microbiological 
reagents were purchased from Sigma–Aldrich unless otherwise specified.  
Silver NPs synthesis: Single step citrate reduction reaction was employed for the preparation 
of AgNPs.  The glassware used for AgNPs synthesis was thoroughly washed with aqua regia 
(HCl and HNO3 in 3:1). Silver nitrate (0.02 % AgNO3 w/v) was dissolved in 100 mL 
deionized water and boiled at 150 °C under continuous stirring. 2 mL of sodium citrate 
solution (1 % Na3C6H5O7 in deionized water) were added to the silver nitrate solution 
dropwise. Then, the solution was left for ~ 30-40 min at 150 °C with stirring. 
LbL coating of AgNPs with aminocellulose and acylase: Negatively charged AgNPs were 
used as colloidal templates for LbL deposition of the positively charged AM and negatively 
charged acylase. AgNPs were diluted (2x) in mQ water and the pH was adjusted to 8. The 




mixing 7.35 mL of the diluted AgNPs with 0.65 mL of 10 mg mL
-1
 of AM (in mQ water) 
deposited as a first layer, and acylase (in 100 mM Tricine buffer, pH 8) as a second layer. The 
samples were agitated for 5 min and were left for 1 h at room temperature. After the AM 
deposition, the NPs were ultracentrifuged at 18 000 rpm for 50 min, while after the acylase 
deposition the centrifugation was carried out for 15 min at 15 000 rpm. Finally, the pellets of 
LbL Ag@AM_AC NPs were collected and resuspended in 1 mL mQ water. In order to 
outline the role of acylase in the hybrid nanoentities, we further developed control NPs 
decorated with non-catalytically active bovine serum albumin (10 mg mL
-1
 BSA), instead of 
QQ acylase. These samples (LbL Ag@AM_BSA NPs) were used as a control in the 
antibacterial test.   
Nanoparticles characterization: Spectrophotometric measurements were performed in a 
microplate reader Infinite M200, Tecan (Austria). The UV–vis spectra were collected in the 
range of 300–600 nm, recording absorbance at a 2 nm step. TEM and dynamic light scattering 
was used to determine the size and the zeta-potential of the Ag NPs. 
The successful buildup of the LbL constructs was studied by measuring the variation of zeta-
potential of the NPs after each layer deposition using a Zetasizer Nano Z (Malvern 
Instruments Inc., U.K.). After the LbL assembly, the size and concentration of the NPs was 
assessed by Nanoparticle Tracking Analyzer (NTA) (NanoSight LM10, Malvern Instruments 
Inc., U.K.) equipped with LM10 Laser 405 nm NP viewing unit and sCMOS camera. 
Software NTA 3.2 Dev Build 3.2.16 was used to capture several frames of the NP suspension 
to obtain the size of particles and their final concentration. The reported average particle size 
represents the mean values ± standard deviations of five measurements per sample. The size 
and morphology of the LbL NPs were also examined by TEM using a TEM JEOL 1010 
equipped with a camera CCD Orius (GATAN) at an operating voltage of 80 kV. The sample 




Enzymatic activity: The enzyme activity of LbL Ag@AM_AC NPs was evaluated by a 
colorimetric assay using N-acetyl-L-methionine (NAMET) as a substrate and in a bioassay 
using C. violaceum CECT 5999. In the colorimetric assay, 200 µL of tricine buffer (100 mM, 
pH 8.0) and 200 µL of 0.5 mM cobalt chloride solution were added to 200 µL samples and 
equilibrated at 37 °C. Then, 200 µL of 100 mM NAMET in tricine buffer (100 mM, pH 8.0) 
were added, and the test tubes were incubated for 30 min. The reaction was stopped by rising 
the temperature to 100 °C for 4 min. The product of the enzymatic reaction was determined 
using the ninhydrin assay as follows: 200 µL of the sample was mixed with 400 µL of 2 % 
(w/v) ninhydrin solution (prepared in 200 mM citrate buffer, pH 5 and ethylene glycol 
monomethyl ether (1:1)) and 20 µL 1.6 % (w/v) stannous chloride solution. The samples were 
incubated for 20 min at 100 °C and cooled down before measuring their absorbance at 570 nm. 
Non-coated AgNPs were used as a control in all the experiments.  
Quorum quenching activity: C. violaceum CECT 5999 was used to test the QQ activity of 
acylase and its ability to interfere with the QS process through the degradation of C6-HSLs, 
as previously described.
[24]
 C. violaceum CECT 5999 is a mutant bacterial strain that in the 
presence of AHLs produces the purple pigment violacein. Briefly, the bacterium was grown 
on Luria Bertani broth (LB) agar (supplemented with 25 μg mL
-1
 kanamycin (Sigma-
Aldrich)), and the plates were incubated at 26 °C for 48 h. Afterwards, the bacterium was 
inoculated in LB medium supplemented with 25 μg mL
-1
 kanamycin at 26 °C for 12-16 h. For 
the bioassay, C. violaceum was diluted to optical density 0.004 (OD660) in fresh medium 
supplemented with 25 μg mL
-1
 kanamycin and 5 μM AHLs (C6-HSL). Then, 350 μL of the 
inoculum were mixed with 350 μL of LbL Ag@AM_AC NPs and uncoated AgNPs template 
at their subinhibitory concentrations, and the samples were left at 26 °C overnight with 550 
rpm shaking. Bacterium without NPs was used as a control. After the time of incubation, 200 
μL of each sample were transferred in 2 mL Eppendorf, mixed with 200 μL of 10 % sodium 




violacein extraction and the samples were centrifuged for 5 min at 13, 000 rpm. The butanol 
phase containing violacein was collected and the absorbance was measured at 584 nm.  
Minimal inhibitory concentration determination: The MIC and MBC of AgNPs and LbL 
Ag@AM_AC NPs were assessed towards the Gram-negative P. aeruginosa. Briefly, bacteria 
were grown overnight at 37 °C in Mueller Hinton Broth (MHB) medium. Subsequently, 50 
µL of different concentration of AgNPs and LbL Ag@AM_AC NPs were mixed with 50 µL 




 colony forming units 
per mL (CFU mL
-1
)) in a 96-well polypropylene microplate and incubated at 37 ºC for 24 h. 
Subsequently, the P. aeruginosa growth in presence of NPs was assessed measuring the OD 
at 600 nm in a microplate reader (Infinite M200, Tecan, Austria). The samples, where no 
turbidity (no bacteria growth) was observed (OD600 ∼0) were considered antibacterial. 
Afterwards, the NPs bactericidal activity was proven by culturing the samples onto selective 
agar and incubating the plates for 16 h at 37 °C.  
Transmission Electron Microscopy of Bacterial Samples:  LbL Ag@AM_AC NPs were 






) for 3h at 37 ºC with 
shaking. Afterwards, the samples were centrifuged at 4000 g for 5 min and resuspended in 
fresh fixative solution containing 2.5 % glutaraldehyde and 2 % paraformaldehyde 0.1M 
phosphate buffer, pH 7.4. The samples were incubated for overnight at 4 °C, washed three 
times with 0.1M phosphate buffer, pH 7.4 and fixed in 1% osmium tetraoxide. Then, the cells 
were stained with 2% uranyl acetate, dehydrated in an ethanol, and embedded in Spurr resin. 
Ultrathin sections were obtained with an Ultracut E (Reichert-Jung) ultramicrotome and 
counterstained with lead citrate. The slices were deposited on bare mesh copper grids and the 
sections were observed using JEOL 1100 transmission electron microscope at 80 kV.  
Determination of reactive oxygen species: 2,7-dichlorodihydrofluorescein diacetate (DCFDA) 
assay was used to quantitatively measurement of ROS produced in the bacterial cells. Briefly, 




subsequently washed in phosphate buffered saline (PBS). Then, the bacterial cells(optical 




 colony forming units per mL (CFU mL
-1
)) were 
resuspended in PBS and were treated AgNPs and LbL Ag@AM_AC NPs with different 
concentrations for 3 h at 37 ºC at 230 rpm . Then, 25 µL of 100 µM  DCFH-DA were added to 
the samples and the fluorescence was measured at Ex/Em = 485/535 nm. AAPH was used as 
a positive control.  
Biofilm Inhibition Test: The antibiofilm activity of the AgNPs and LbL Ag@AM_AC NPs 
against Gram-negative P. aeruginosa was evaluated using colorimetric crystal violet and 
Live/Dead assays. Briefly, 50 μL of the NPs and 50 μL of bacteria in tryptic soy broth (TSB) 
(OD600 = 0.01) were placed in a 96-well microplate. The microplate was then incubated for 24 
h at 37 °C under static conditions to allow bacteria to form biofilm. After the incubation, the 
non-adhered bacterial cells were washed three times with 200 μL distilled H2O. The 
microplate was incubated for 60 min at 60 °C for biofilm fixation. The total biomass was 
determined using crystal violet assay. The biofilm was stained for 5−10 min with 200 μL of 
0.1 % (w/v) crystal violet solution, washed three times with distilled H2O, and dried at 60 °C. 
Next, 200 μL of 30 % (v/v) acetic acid were added to dissolve the crystal violet and the plate 
was incubated for 15 min at room temperature. After that, 125 μL of each well were 
transferred to a new 96-well microplate, and the absorbance was measured at 595 nm. The 
amount of the dye is directly proportional to the total biomass on the surface, including 
bacteria cells and the extracellular matrix. Gentamicin (100 μg mL
-1
) was used as a positive 
control (biofilm inhibition).  
The live and dead bacteria into the biofilms were further observed with fluorescence 
microscopy using Live/dead™ BacLight™ kit, which is comprised of the two nucleic acid 
fluorescent dyes, SYTO9 and propidium iodide (PI). After the incubation, the non-adhered 




incubated with 20 µL of SYTO9 and PI in ratio 1:1. After 15 min of incubation in a dark, the 
samples were visualised under fluorescence microscopy using 20x objective lens. The live 
cells were stained in green and the dead ones in red. 
Biofilm Eradication assay: The effect of the NPs on the already established P. aeruginosa 
biofilm was studied using crystal violet and Live/Dead assays. 100 μL of bacteria in TSB 
(OD600 = 0.01) were placed 96-well microplate and the biofilm was allowed to form for 24 h 
at 37 °C under static conditions and the planktonic cells were washed with sterile PBS. 60 μL 
of NPs and 60 μL of TSB were placed in the 96-well microplate, subsequently left for 24 h at 
37 °C under static conditions. After the incubation, the non-adhered bacterial cells were 
washed three times with 200 μL sterile PBS. For determination of the total biofilm mass the 
biofilms were left for fixation for 1 h at 60 °C. Then, the formed biofilms were stained with 
crystal violet (0.1 % w/v) and dried at 60 °C and further dissolved using 30 % (v/v) acetic 
acid. 125 μL were transferred into 96-well microplate and the absorbance was recorded at 595 
nm.  The live and dead bacteria were observed using fluorescence microscopy (20x objective 
lens) after incubation with 20 µL of SYTO9 and PI in ratio 1:1.  
Biocompatibility of the NPs: The cytotoxicity of the developed LbL coated AgNPs towards 
mammalian cells was evaluated using human fibroblast cell line BJ-5ta. The LbL 
Ag@AM_AC NPs were placed in contact with the previously seeded cells and after 24 h the 
number of viable cells was quantified using Alamar Blue assay (AlamarBlue®, Invitrogen) as 
described previously.
[8,45]
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Figure 1. LbL Ag@AM_AC NPs preparation and characterization. A) Schematic 
representation of AgNPs template coating with AM and AC using LbL approach. (B) Zeta-
potential of the NPs after each layer deposition. C, D) TEM images of LbL Ag@AM_AC 
NPs at different magnifications. E) Histogram of LbL Ag@AM_AC NPs size distribution 
based on the total count using ImageJ software. F) Elemental mapping image and G) STEM-








Figure 2. Violacein production by C. violaceum. A) The AHL signals bind to the cytoplasmic 
QS receptor and switches on the vio genes, activating the violacein production (left). The 
presence of QQ active NPs breaks down the AHL signals, silencing the expression of the vio 
genes, subsequently inhibiting the violacein production (right). B) Quantification of QS 
regulated violacein production (%) by C. violaceum and C) Representative images of 







Figure 3. A) P. aeruginosa growth after 24 h incubation with AgNP template and LbL 
Ag@AM_AC NPs at different concentrations. TEM images of P. aeruginosa before B) and 








Figure 4. P. aeruginosa biofilm inhibition. A) MBIC determination of the NPs using crystal 
violet assay. B) Live/dead™ BacLight™ kit microscopic visuali ation. The green and red 
fluorescence images are overlaid. Nonviable bacteria are stained in red, while the viable 







Figure 5. Elimination of 24h grown P. aeruginosa biofilm. A) MBEC determination of the 
NPs using crystal violet assay. B) Live/dead™ BacLight™ kit microscopic visuali ation of P. 





). The green and red fluorescence images are overlaid. 












Figure 6. Cytotoxicity evaluation. A) Viability (%) of human fibroblasts exposed to AgNPs 
and LbL Ag@AM_AC NPs after 24 h of incubation assessed by the AlamarBlue assay. B) 
Live/Dead assay of human fibroblasts after 24 h exposure to AgNPs and LbL Ag@AM_AC 






Antimicrobial silver nanoparticles (AgNPs) are decorated in a Layer-by-Layer fashion 
with toppositely charged aminocellulose (AM) and acylase to generate hybrid 
nanoentities with enhanced antibacterial and antibiofilm activities as well as reduced 
cytotoxicity. The hybrid nanoparticles in 8-fold lower concentration than the pristine AgNPs, 
inhibit QS-regulated virulence factors and reduce by 100 % the P. aeruginosa biofilm 
formation.  
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